Evaluation of Performance and Safety of Eye Drops With Hyaluronic Acid 0.30% and 0.15%
NCT: NCT06189456 · COMPLETED
Brief Summary
This is a profit, multicentric, prospective, open-label, non-pharmacological clinical investigation aim to evaluate the efficacy and tollerability of two types of eye drops containing Hyaluronic acid (HA) with different concentration as 0.30% (BLUgel A) and 0.15% (BLUyal A). the study will consider patients affected by moderate to severe dry eye syndrome which will be treated with HA 0.30% while patients affected by mild dry eye syndrome will be treated with HA 0.15%.Dry eye syndrome (DES) is defined as a multifactorial disease of the ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface.Based on the available background on the use of HA in the management of DES, this investigation has been designed to assess the efficacy of HA- and amino acid-based product BLUgel A free and BLUyal A free, in patients with moderate to severe and mild dry eye syndrome, respectively.
Frequently Asked Questions
What is Evaluation of Performance and Safety of Eye Drops With Hyaluronic Acid 0.30% and 0.15%?
Evaluation of Performance and Safety of Eye Drops With Hyaluronic Acid 0.30% and 0.15% is a clinical trial registered under NCT06189456. Current status: COMPLETED.
What is the status of NCT06189456?
The current status of NCT06189456 (Evaluation of Performance and Safety of Eye Drops With Hyaluronic Acid 0.30% and 0.15%) is: COMPLETED.
When did Evaluation of Performance and Safety of Eye Drops With Hyaluronic Acid 0.30% and 0.15% start?
Evaluation of Performance and Safety of Eye Drops With Hyaluronic Acid 0.30% and 0.15% started on 2023-06-21.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.